Brand Name(s):Quinsair nebuliser system
Indication:Chronic pulmonary infections (management of) due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
The MHRA has informed healthcare professionals about a small increased risk of heart valve regurgitation with fluoroquinolone antibiotics. Fluoroquinolones should only be used after careful benefit-risk assessment, and after consideration of other therapeutic options in people at risk for heart valve regurgitation (incompetence). March ’21
Drug Safety Update
Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients